Two MicroPort® EP Diagnostic Catheters Approved in Australia

Shanghai, China—[Saturday 19 September 2020] - Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) has recently obtained registration approval from Australia’s Therapeutic Goods Administration (TGA) for its proprietary EasyFinder™ Fixed Curve Diagnostic Catheter and EasyFinder™ Steerable Curve Diagnostic Catheter.

Severe arrhythmia is the main cause of sudden cardiac death. MicroPort® EP has developed a line of proprietary products, such as the Ablation Catheter, Diagnostic Catheter, 3D EP Navigation System, RF Generator, and Irrigation Pump, for use in radiofrequency ablation among patients with arrhythmias. Of these products, the Diagnostic Catheter is mainly used in the diagnosis of arrhythmia. The EasyFinder™ Fixed and Steerable Curve Diagnostic Catheter can be used in conjunction with a polygraph or a stimulator to navigate electrocardiosignals during EP examinations and surgeries, while the EasyFinder™ Steerable Curve Diagnostic Catheter allows for the mapping of multiple body parts, which helps to improve procedural efficiency and reduce radiation exposure to surgeons and patients.

Earlier in the first half of this year, a series of products developed by MicroPort® EP, including the FireMagic® Cardiac RF Ablation Catheter, FireMagic® 3D Irrigated Ablation Catheter, EasyLoop® Circular Mapping Catheter, Columbus™ External Reference Patch and FORLNK™ Cables, have successfully entered the Australian market. The two Diagnostic Catheters, now TGA approved, will better complement the RF Ablation Catheter and other products already on the market, providing an integrated cardiac-electrophysiological medical solution for local patients and physicians, while laying a solid foundation for the further expansion of MicroPort® EP into the Oceania market.